Despite Being First Mover, BioMarin's Voxzogo For Dwarfism To Face Pressure From Ascendis' Candidate In Near Term
BioMarin stock dips in response to TransCon CNP data, as analysts note TransCon CNP could challenge BioMarin's Voxzogo by ...
FierceBiotech6d
Ascendis' dwarfism drug accelerates growth in phase 3, teeing up challenge to BioMarin
BioMarin serves that need with its CNP analog Voxzogo—the centerpiece of its growth strategy—but that drug needs to be ...
Ascendis Pharma's Rare Dwarfism Candidate Shows Promise In Trial, FDA Submission Expected Next Year
Ascendis Pharma reports positive topline data from the Phase 3 ApproaCH trial of TransCon CNP in children with achondroplasia ...
Pivotal ApproaCH Trial of TransCon™ CNP (Navepegritide) Achieved Primary Objective, Demonstrated AGV Superior to Placebo
TransCon CNP demonstrated AGV superior to placebo with LS mean treatment difference of 1.49 cm/year at Week 52 (p<0.0001)– For ...
Ascendis Challenges BioMarin, But Market Response Seems Excessive
Ascendis' TransCon CNP showed similar efficacy to BioMarin's Voxzogo but offers once-weekly dosing. Learn more on BMRN and ...
BioMarin off 17% as Ascendis data seen as threat to Voxzogo
BioMarin Pharmaceutical (NASDAQ:BMRN) is down ~17% Monday following positive data from an Ascendis Pharma ...
Zacks.com on MSN6d
Ascendis Soars on Encouraging Data From Dwarfism Drug Study
Shares of Ascendis Pharma ASND rose 17% on Monday after it reported top-line results from the pivotal ApproaCH study that ...
Ascendis Pivotal ApproaCH Study Of TransCon CNP In Achondroplasia Meets Primary Goal; Stock Up
(RTTNews) - Ascendis Pharma A/S (ASND) Monday said the pivotal ApproaCH study of TransCon CNP, in children with achondroplasia met its primary goal. The company's shares were more than 17 percent up ...
Morningstar7d
Pivotal ApproaCH Trial of TransCon™ CNP (Navepegritide) Achieved Primary Objective, Demonstrated AGV Superior to Placebo
TransCon CNP demonstrated AGV superior to placebo with LS mean treatment difference of 1.49 cm/year at Week 52 (p<0.0001) – For children aged 5-11 years TransCon CNP demonstrated a change ...
Yahoo Finance7d
Pivotal ApproaCH Trial of TransCon™ CNP (Navepegritide) Achieved Primary Objective, Demonstrated AGV Superior to Placebo
16, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced topline data from the pivotal double-blind placebo-controlled ApproaCH Trial of TransCon CNP (navepegritide), which ...
Stockhouse7d
Pivotal ApproaCH Trial of TransCon(TM) CNP (Navepegritide) Achieved Primary Objective, Demonstrated AGV Superior to Placebo
TransCon CNP demonstrated AGV superior to placebo with LS mean treatment difference of 1.49 cm/year at Week 52 (p<0.0001) – For children aged 5-11 years TransCon CNP demonstrated a change from ...
Mena FN7d
Pivotal Approach Trial Of Transcon™ CNP (Navepegritide) Achieved Primary Objective, Demonstrated AGV Superior To Placebo
(MENAFN- GlobeNewsWire - Nasdaq) – TransCon CNP demonstrated AGV superior to placebo with LS mean treatment difference of 1.49 cm/year at Week 52 (p<0.0001) – For children aged 5-11 years ...